Hormone therapy and risk of venous thromboembolism among postmenopausal women-Reference-Cited by-同舟云学术

Hormone therapy and risk of venous thromboembolism among postmenopausal women

Published:2015-11 Issue:3 Volume:82 Page:304-307
ISSN:0378-5122
Container-title:Maturitas
language:en
Short-container-title:Maturitas

Author:

Canonico Marianne

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,General Biochemistry, Genetics and Molecular Biology

Reference35 articles.

1. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP study group. Groupe d'Etude de la Thrombose de Bretagne Occidentale;Oger;Thromb. Haemost.,2000

2. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women;Olie;Curr. Opin. Hematol.,2010

3. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. A report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center, N. Engl. J. Med. (1974) 290(1) 15–19.

4. Risk of venous thromboembolism in users of hormone replacement therapy;Daly;Lancet,1996

5. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens;Jick;Lancet,1996

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genome-wide investigation of exogenous female hormones, genetic variation, and venous thromboembolism risk;Journal of Thrombosis and Haemostasis;2024-08

2. Reduced protein carbonylation on hormone therapy is associated with improved fibrinolysis in postmenopausal women: the impact of PAI-1 and TAFI activity;Journal of Thrombosis and Thrombolysis;2024-07-09

3. Menopausal hormone therapy and risk of venous thromboembolism: The story so far;AFR J REPROD HEALTH;2024

4. Low thrombin generation in postmenopausal women using estetrol;Climacteric;2024-01-19

5. Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy;Menopausal Review;2023